Clinical Trial Update: A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2, single-arm, open-label study evaluating GS-1101 (CAL-101) for previously treated chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• GS-1101 (CAL-101) – idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN